FindTrial
Sign In

A clinical trial to find out the genetic association in congenital adrenal hyperplasia

Molecular genetic analysis of Congenital Adrenal Hyperplasia due to 21-hydroxylase deficiency in patients attending tertiary care hospital in Madurai, South India - CAH

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/05/025128
Enrollment
25
Registered
2020-05-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E250- Congenital adrenogenital disordersassociated with enzyme deficiency

Interventions

None listed

Sponsors

MultiDisciplinary Research Units DHR ICMR
Lead Sponsor
Government of Tamilnadu
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: All Congenital Adrenal Hyperplasia patients due to 21 hydroxylase deficiency attending outpatient endocrine clinic of Government Rajaji Hospital, Madurai

Exclusion criteria

Exclusion criteria: Non 21 hydroxylase deficiency

Design outcomes

Primary

MeasureTime frame
To assess the nature of mutations of CYP21A2 gene in patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency.Timepoint: To assess the nature of mutations of CYP21A2 gene in patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency.—

Secondary

MeasureTime frame
To correlate the various CYP21A2 gene mutations with their clinical expression and the hormonal profile.Timepoint: Two Years—

Countries

India

Contacts

Public ContactDr S Sridhar MD DM Endo

Madurai Medical College

drsridharjipmer@gmail.com9789720246

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026